(MENAFN- ProactiveInvestors)
Next Thursday’s event brings together three growth companies with different backgrounds that have one thing in common – huge potential.
Horizon Discovery () Clinigen () and () are joining us for an update to their latest developments.
To ensure you don't miss out on the event on March 26 secure your place HERE.
Clinigen Group is laying down the blueprint for the next generation of mid-cap biotechs. It has three divisions - speciality pharma access programs and clinical trials - all of which are tipped for strong growth in the coming years.
Deals recently with and Raptor Pharmaceutical underlined the speed and scale of progress but chief executive Peter George says more are on the way. For example the group has just extended its exclusive US distribution for leading product Foscavir. The five year extension will mean continued distribution of anti-viral treatment for AIDS-related conditions.
Clinigen’s share price has jumped 10% in the past three months. Shaun Chilton chief operating officer is joining us to explain the significance of the recent moves and the many opportunities open to the company.
Horizon Discovery is leading the way in research tools services and intellectual property for pharma and biotech companies. Horizon recently revealed it had joined a select band of companies who can claim to have won "Business of the Year" twice at the Business Weekly awards.
Having first won the accolade now in its 25th year in 2011 Horizon has transformed from a private UK life science business in Cambridge to a publicly-listed international life science group employing more than 230 staff across the UK Austria and the US.
It is rapidly growing with more than 950 organisations using its services a third more than last year including 30 of the top 50 pharma and biotech companies.
Chief Executive Darrin Disley is confident their research into the development of new tools will create a new generation of high value biopharmaceuticals.
Recently the company along with two partners was chosen to develop the next generation of UK biological medicines.
Broker N+1 Singer described the project win as highlighting Horizon Discovery’s rapid development.
Disley who was recently named Executive of the Year at the SCRIP Awards 2014 joins us to explain what is a very fast–evolving story.
is an opportunity to buy into Birmingham’s re-emergence as a major economic centre in Britain says chief executive Paul Bassi.
The UK’s second city is one of the first places firms now consider if they move out of London he says and an extensive local knowledge has seen the group put together a handy-sized portfolio of industrial properties just as yields start to fall.
Last year the portfolio was worth more than £100mln but the company has plans to double this.
Shares have risen by 30% over 12 months and the group has already a promised a 1.5p dividend for the year to December a 50% hike for a current yield of 2.4%. Recent conversion to an investment trust will also boost earnings.
Joining us to explain the story is chief executive Paul Bassi.
The evening will end at 7pm with a complimentary bar and an assortment of hot & cold canapes giving you the opportunity to speak with the directors and other investors.
Please join us at 5:45pm to allow for a prompt 6pm start. Each company has 20 minutes to give a short presentation and then 10 minutes Q&A.
This will be followed by the 'Champagne Raffle' where six guests will win a bottle each. The event will be rounded off with a drinks reception with canapés.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.